Current therapy for chronic hepatitis C

Gastroenterology

Volumn 118, Issue 2 SUPPL., 2000, Pages

  Davis, Gary L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

BLOOD TOXICITY; DRUG MEGADOSE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT OUTCOME;

EID: 0033965268     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(00)70009-6     Document Type: Article

References (107)

1. M Alter D Kruszon-Moran OV Nainan The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
2. A Spaulding C Greene K Davidson M Schneidermann J. Rich Hepatitis C in state correctional facilities Prev Med 28 1999 92 100
3. MJ Alter SC Hadler FN Judson Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection JAMA 264 1990 2231 2235
4. JM Sànchez-Tapias JM Barrera J Costa Hepatitis C virus infection in patients with nonalcoholic chronic liver disease Ann Intern Med 112 1990 921 924
5. RA Meyer SC. Gordon Epidemiology of hepatitis C virus infection in a suburban Detroit community Am J Gastroenterol 86 1991 1224 1226
6. MJ. Alter The epidemiology of acute and chronic hepatitis C Clin Liver Dis 1 1997 559 568
7. LB Seeff Z Buskell-Bales EC Wright Long-term mortality after transfusion-associated non-A, non-B hepatitis N Engl J Med 327 1992 1906 1911
8. HB El-Serag AC. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750
9. Primary Liver Disease of Liver Transplant Recipients 1991 and 1992 (From the UNOS Scientific Registry) UNOS Update 9 1993 27
10. JH Hoofnagle KD Mullen DB Jones Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report N Engl J Med 315 1986 1575 1578
11. GL Davis LA Balart ER Schiff Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled study N Engl J Med 321 1989 1501 1506
12. AM DiBisceglie P Martin C Kassianides Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-bind, placebo-controlled trial N Engl J Med 321 1989 1506 1510
13. T Poynard V Leroy M Cohard Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration Hepatology 24 1996 778 789
14. JG McHutchison S Gordon ER Schiff Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: results of a U.S. multicenter randomized controlled study N Engl J Med 339 1998 1485 1492
15. T Poynard P Marcellin S Lee Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
16. GL Davis R Esteban-Mur V Rustgi Recombinant interferon alfa-2b (Intron A) alone or in combination with ribavirin (Rebetol) for retreatment of interferon relapse in chronic hepatitis C N Engl J Med 339 1998 1493 1499
17. M Peters GL Davis JS Dooley The interferon system in acute and chronic viral hepatitis. Progress in liver diseases H eds Popper F Schaffner 1986 Grune & Stratton, New York 453 467
18. S Khakoo P Glue L Grellier Ribavirin and interferin alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions Br J Clin Pharmacol 46 1998 563 570
19. P Glue Y Tan M Sack S Shenker D Zambas SK Gupta RP. Clement Use of ribavirin in patients with renal and hepatic dysfunction: pharmacokinetic data and recommendations Hepatology 30 1999 309A (abstr)
20. CS. Crumpacker Overview of ribavirin treatment of infection caused by RNA viruses. In Clinical applications of ribavirin RA eds Smith V Knight JAD Smith 1984 Academic, Orlando, FL 33 38
21. O Reichard J Andersson R Schvarcz Ribavirin treatment for chronic hepatitis C Lancet 337 1991 1058 1061
22. AM Di Bisceglie M Shindo T-L Fong Pilot study of ribavirin therapy for chronic hepatitis C Hepatology 16 1992 649 654
23. G Dusheiko J Main H Thomas Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study J Hepatol 25 1996 591 598
24. HC Bodenheimer KL Lindsay GL Davis Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial Hepatology 26 1997 473 477
25. GL. Davis Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C Semin Liver Dis 19 1999 49 55
26. O Reichard G Norkrans A Fryden Alfa-interferon and ribavirin versus alfa-interferon alone as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled study Lancet 351 1998 83 87
27. L Nyberg J McHutchison J Albrecht M Elliot A. Conrad Early changes in HCV RNA kinetics with interferon and ribavirin compared to interferon alone suggest an additive antiviral effect with ribavirin Hepatology 26 1997 367A (abstr)
28. S Zeuzem JM Schmidt JH Lee Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover Hepatology 28 1998 245 252
29. JM Pawlotsky H Dahari A Conrad Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus genotype 1b replication kinetics and clearance Hepatology 28 1998 288A (abstr)
30. JL Patterson R. Fernandez-Larson Molecular action of ribavirin Rev Infect Dis 12 1990 1132 1146
31. Q Ning D Brown J Parodo Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, and procoagulant activity and preserves TH1 cytokine production, but inhibits TH2 cytokine response J Immunol 160 1998 3487 3493
32. J Martin S Navas JA Quiroga Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients Cytokine 10 1998 635 644
33. S Kakumu K Yoshioka T Wakita A pilot study of ribavirin and interferon beta for the treatment for chronic hepatitis C Gastroenterology 105 1993 507 512
34. JH Braconier O Paulsen K Engman A. Widell Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study Scand J Infect Dis 27 1995 325 329
35. L Chemello L Cavaletto E Bernardinello M Guido P Pontisso A. Alberti The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C J Hepatol 23 1995 8 12
36. MY Lai JH Kao PM Yang Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C Gastroenterology 111 1996 1307 1312
37. GL. Davis Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C Semin Liver Dis 19 1999 49 55
38. JG McHutchison T. Poynard Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C Semin Liver Dis 19 1999 57 65
39. GL Davis JYN. Lau Factors predictive of a beneficial response to therapy of hepatitis C Hepatology 26 1997 122 127
40. SW Schalm O Weiland BE Hansen Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled studies Gastroenterology 117 1999 408 413
41. A Alberti L Chemello F Noventa L Cavalletto G. De Salva Therapy of hepatitis C: retreatment with alpha interferon Hepatology 26 1997 137 142
42. P Marcellin M Pouteau N Boyer C Castelnau S Erlinger JP. Benhanou Retreatment with recombinant interferon-alfa in patients with chronic hepatitis C J Infect Dis 167 1993 780 781
43. A Picciotti R Brizzolara N Campo Two year interferon retreatment may induce a sustained response in relapsing patients with chronic hepatitis Hepatology 24 1996 273A (abstr)
44. EJ Heathcote EB Keeffe SS Lee Retreatment of chronic hepatitis C with consensus interferon Hepatology 27 1998 1136 1143
45. S Brillanti J Garson M Foli A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C Gastroenterology 107 1994 812 817
46. A Bellobuono L Mondazzi S Tempini E Silini F Vicari G. Ideo Ribavirin and interferon alpha combination therapy vs interferon alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial J Viral Hepat 4 1997 185 191
47. M Caremani A Benci R Castellacci D. Tacconi A randomized controlled trial of leukocyte IFN alfpha + ribavirin in HCV chronic hepatitis relapsing patients Hepatology 24 1996 395A (abstr)
48. GL Davis R Estaban-Mur V Rustgi The International Hepatitis Interventional Therapy Group. Retreatment of relapse after interferon therapy for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone N Engl J Med 339 1998 1493 1499
49. S Brillanti J Garson M Foli A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C Gastroenterology 107 1994 812 817
50. S Pol P Berthelot C Brechot French Multicenter Study Group A randomized trial of ribavirin and interferon alpha vs. interferon alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment J Hepatol 31 1999 1 7
51. G Scotto V Fazio G. Tantimonaco Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic hepatitis C not responding to alpha-interferon alone Ital J Gastroenterol 28 1996 505 511
52. G Barbaro G Di Lorenzo G Belloni Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial Am J Med 107 1999 112 118
53. R Sostegni V Ghisetti F Pittaluga Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial Hepatology 28 1998 341 346
54. P Andreone A Gramenzi C Cursaro Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial J Hepatol 30 1999 788 793
55. H Bell K Hellum S Harthug Treatment with interferon-alpha2a alone or interferon alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-apha2a Scand J Gastroenterol 34 1999 194 198
56. EL Krawitt R Albertini A John Interim results of the NYNEST interferon: ribavirin retreatment trial in chronic hepatitis C non-responders Hepatology 28 1998 375A (abstr)
57. J Moussalli V Ratziu V Di Martino Combination therapy with interferon and ribavirin induces response in patients with chronic hepatitis C non-responders to interferon responders Hepatology 28 1998 478A (abstr)
58. AD Min J Jones S Esposito Interferon alfa-2b and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon responders Hepatology 28 1998 286A (abstr)
59. JA Moreno-Monteagudo L Garcia-Buey M Fernandez-Bermejo Interferon plus ribavirin in interferon non-responders or relapsing chronic hepatitis C patients: end-of-treatment response and sustained response at third follow-up month responders Hepatology 28 1998 476A (abstr)
60. BR Bacon JA Rauscher NL Smith-Wilkaitis Interferon-ribavirin combination is successful in eliminating hepatitis C virus in non-responders to interferon alone including patients with normal aminotransferases responders Hepatology 28 1998 372A (abstr)
61. EJ Heathcote S James K Mullen Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon Hepatology 30 1999 562 566
62. KL Lindsay GL Davis ER Schiff Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial Hepatology 24 1996 1034 1040
63. ML. Shiffman Use of high-dose interferon in the treatment of chronic hepatitis C Semin Liver Dis 19 1999 25 33
64. NP Lam AU Neumann DR Gretch TE Wiley AS Perelsen TJ. Layden Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa Hepatology 26 1997 226 231
65. WC. Maddrey Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C: relapsed and treatment-nave patients Semin Liver Dis 19 1999 67 75
66. CK Weisz S Kreiswirth M McMeeking Erythropoietin use for ribavirin/interferon induced anemia in patients with hepatitis Hepatology 28 1998 288A (abstr)
67. GL. Davis Interferon treatment of cirrhotic patients with chronic hepatitis C: a logical intervention Am J Gastroenterol 89 1994 658 660 (editorial)
68. DC Valla M Chevallier P Marcellin Treatment of hepatitis C virus-related cirrhosis: a randomized controlled trial of interferon alfa-2b versus no treatment Hepatology 29 1999 1870 1875
69. H Yoshida Y Shiratori M Moriyama Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan Ann Intern Med 131 1999 171 181
70. M Shindo A Ken T. Okuno Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy Cancer 85 1999 1943 1950
71. K Ikeda S Saitoh Y Arase Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis Hepatology 29 1999 1124 1130
72. T Okanoue Y Itoh M Minami Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not in an advanced stage: a retrospective study in 1148 patients J Hepatol 30 1999 653 659
73. R Sobesky P Mathurin F Charlotte Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view Gastroenerology 116 1999 378 386
74. P Mathurin J Moussalli J-F Candranel Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity Hepatology 27 1998 868 872
75. L Serfaty O Chazouilleres JM Pawlotsky Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity Gastroenterology 110 1996 291 295
76. F Lunel L Musset P Cacoub Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage Gastroenterology 106 1994 1291 1300
77. AP Limaye RA Schmidt RW Glenny CL Davis KV. Kowdley Successful treatment of severe hepatitis C-associated pulmonary vasculitis in a liver transplant recipient Transplantation 65 1998 998 1000
78. E Zuckerman G Slobodin A Tamir Treatment of refractory symptomatic HCV-related mixed cryoglobulinemia with ribavirin and interferon alfa Hepatology 28 1998 374A (abstr)
79. C Donada A Crucitti V Donadon Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia Blood 92 1998 2983 2984 (letter)
80. JL Calleja A Albillos R Moreno-Otero Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia Aliment Pharmacol Ther 13 1999 1179 1186
81. P Cresta L Musset P Cacoub Response to interferon alpha treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus Gut 45 1999 122 128
82. HP Pham C Feray D Samuel Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients Kidney Int 54 1998 1311 1319
83. JM Durand P Cacoub F Lunel-Fabiani Ribavirin in hepatitis C related cryoglobulinemia J Rheumatol 25 1998 1115 1117
84. GP Ilyin S Langouet M Rissel Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes Hepatology 27 1998 1687 1694
85. RJ Johnson DR Gretch H Yamabe Membranoproliferative glomerulonephritis associated with hepatitis C virus infection N Engl J Med 328 1993 465 470
86. H Yamabe RJ Johnson DR Gretch Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha Am J Kidney Dis 25 1995 67 69
87. A Komatsuda H Imai H Wakui Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy Intern Med 35 1996 529 533
88. F Fabrizi C Pozzi M Farina Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal Nephrol Dial Transplant 13 1998 1991 1997
89. DT Dieterich JM Purow R. Rajapaksa Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV Semin Liver Dis 19 1999 87 94
90. DL Thomas JW Shih HJ Alter Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users J Infect Dis 174 1996 690 695
91. J Garcia-Samiego V Soriano J Castilla Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C Am J Gastroenterol 92 1997 1130 1134
92. B Soto A Sanchez-Quijano L Rodrigo Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis J Hepatol 26 1997 1 5
93. ME Eyster LS Diamondstone JM Lien WC Ehmann S Quan JJ. Goedert Natural history of hepatitis C virus infection in multi-transfused hemophiliacs: effect of co-infection with human immunodeficiency virus J Acquir Immune Defic Syndr Hum Retrovirol 6 1993 602 610
94. SM Sim PG Hoggard SD Sales D Phiboonbanakit CA Hart DJ. Back Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction AIDS Res Hum Retroviruses 14 1998 1661 1667
95. NR Hartman GS Ahluwalia DA Cooney Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine Mol Pharmacol 40 1991 118 124
96. TL Wright E Donegan HH Hsu Recurrent and acquired hepatitis C viral infection in liver transplant recipients Gastroenterology 103 1992 317 322
97. G Gotz MR Schon A Haefker Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin Transplant Proc 30 1998 2104 2106
98. SF Dodson H Vargas O Shakil Final analysis of ribavirin and alpha-interferon for the treatment of hepatitis C infection after liver transplantation Hepatology 28 1998 262A (abstr)
99. T Bizollon U Palazzo C Ducerf Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation Hepatology 26 1997 500 504
100. P Marcellin N Boyer C Degott M Martinot-Peignoux V Duchatelle E Giostra Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon Liver 14 1994 302 307
101. M Yano H Kumada M Kage The long-term pathological evolution of chronic hepatitis C Hepatology 23 1996 1334 1340
102. T Poynard J McHutchinson GL Davis R Esteban-Mur Z Goodman P Bedossa J Albrecht FIBROVIRC Project Group Impact of interferon and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C Hepatology 28 1998 497A (abstr)
103. GL Davis JE Albright SF Cook DM. Rosenberg Projecting the future healthcare burden from hepatitis C in the United States Hepatology 28 1998 390A (abstr)
104. JB Wong GL Davis SG. Pauker Cost-effectiveness of ribavirin and interferon alfa-2b after interferon relapse in chronic hepatitis C Am J Med 2000 (in press)
105. HL Bonkovsky JM Woolley Consensus Interferon Study Group Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy Hepatology 29 1999 264 270
106. JE Ware MS Bayliss M Mannocchia GL Davis International Hepatitis Interventional Therapy Group Health-related quality of life in chronic hepatitis C: impact of disease and treatment response Hepatology 30 1999 550 555
107. DK Pettit TP Bonnert J Eisenman Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling J Biol Chem 272 1997 2312 2318